Multiple myeloma biology: lessons from the 5TMM models

被引:88
作者
Vanderkerken, K
Asosingh, K
Croucher, P
Van Camp, B
机构
[1] Free Univ Brussels, Dept Hematol & Immunol, B-1090 Brussels, Belgium
[2] Nuffield Orthopaed Ctr, Nuffield Dept Orthopaed Surg, Oxford OX3 7LD, England
关键词
D O I
10.1034/j.1600-065X.2003.00035.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multiple myeloma (MM) is a B cell neoplasm characterized by the monoclonal proliferation of plasma cells in the bone marrow, the development of osteolytic lesions and the induction of angiogenesis. These different processes require three-dimensional interactions, with both humoral and cellular contacts. The 5TMM models are suitable models to study these interactions. These murine models originate from spontaneously developed myeloma in elderly mice, which are propagated by in vivo transfer of the myeloma cells into young syngeneic mice. In this review we report on studies performed in the 5TMM models with special emphasis on the homing of the myeloma cells, the characterization of the migrating and proliferating clone and the identification of the isotype switch variants. The bone marrow microenvironment was further targeted with osteoprotegerin (OPG) to block the RANK/RANKL/OPG system and with potent bisphosphonates. Both treatments resulted in a significant protection against myeloma-associated bone disease, and they decreased myeloma disease, as evidenced by a lower tumor load and an increased survival of the mice. These different studies demonstrate the strength of these models, not only in unraveling basic biological processes but also in the testing of potentially new therapeutic targets.
引用
收藏
页码:196 / 206
页数:11
相关论文
共 65 条
[31]   The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis [J].
Joshua, D ;
Petersen, A ;
Brown, R ;
Pope, B ;
Snowdon, L ;
Gibson, J .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 94 (01) :76-81
[32]   OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis [J].
Kong, YY ;
Yoshida, H ;
Sarosi, I ;
Tan, HL ;
Timms, E ;
Capparelli, C ;
Morony, S ;
Oliveira-dos-Santos, AJ ;
Van, G ;
Itie, A ;
Khoo, W ;
Wakeham, A ;
Dunstan, CR ;
Lacey, DL ;
Mak, TW ;
Boyle, WJ ;
Penninger, JM .
NATURE, 1999, 397 (6717) :315-323
[33]   Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation [J].
Lacey, DL ;
Timms, E ;
Tan, HL ;
Kelley, MJ ;
Dunstan, CR ;
Burgess, T ;
Elliott, R ;
Colombero, A ;
Elliott, G ;
Scully, S ;
Hsu, H ;
Sullivan, J ;
Hawkins, N ;
Davy, E ;
Capparelli, C ;
Eli, A ;
Qian, YX ;
Kaufman, S ;
Sarosi, I ;
Shalhoub, V ;
Senaldi, G ;
Guo, J ;
Delaney, J ;
Boyle, WJ .
CELL, 1998, 93 (02) :165-176
[34]   The microenvironment of the tumour-host interface [J].
Liotta, LA ;
Kohn, EC .
NATURE, 2001, 411 (6835) :375-379
[35]   Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6 [J].
Mahmoud, MS ;
Ishikawa, H ;
Fujii, R ;
Kawano, MM .
BLOOD, 1998, 92 (10) :3887-3897
[36]   THE MATRIX-DEGRADING METALLOPROTEINASES [J].
MATRISIAN, LM .
BIOESSAYS, 1992, 14 (07) :455-463
[37]   Chemokine receptor homo- or heterodimerization activates distinct signaling pathways [J].
Mellado, M ;
Rodríguez-Frade, JM ;
Vila-Coro, AJ ;
Fernández, S ;
de Ana, AM ;
Jones, DR ;
Torán, JL ;
Martínez-A, C .
EMBO JOURNAL, 2001, 20 (10) :2497-2507
[38]   The F-actin content of multiple myeloma cells as a measure of their migration [J].
Menu, E ;
Braet, F ;
Timmers, M ;
Van Rieta, I ;
Van Camp, B ;
Vanderkerken, K .
CELL SIGNALING, TRANSCRIPTION, AND TRANSLATION AS THERAPEUTIC TARGETS, 2002, 973 :124-134
[39]  
Noël A, 1997, INVAS METAST, V17, P221
[40]   Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes [J].
Nykjaer, A ;
Conese, M ;
Christensen, EI ;
Olson, D ;
Cremona, O ;
Gliemann, J ;
Blasi, F .
EMBO JOURNAL, 1997, 16 (10) :2610-2620